Sickle Cell Disease Treatment Market Analysis, Trends, and Scope 2023 to 2030
Sickle Cell Disease Treatment Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 1.16 Billion |
| Market Size by 2030 | US$ 4.69 Billion |
| Global CAGR (2022 - 2030) | 19.1% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Treatment
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
Competitive Landscape and Key Companies:
A few of the prominent players operating in the global sickle cell disease treatment market are Novartis AG, Pfizer Inc, Emmaus Life Sciences Inc, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Siklos, Mylan NV, Taj Pharmaceuticals Limited, and Apotex. These companies focus on the development of new technologies, advancements in existing products, and expansion of geographic footprint to meet the growing consumer demand worldwide and expand their product range in specialty portfolios. Companies operating in the global sickle cell disease treatment market are implementing various inorganic and organic strategies. A few of them are mentioned below:
- In April 2023, the US FDA offered Editas Medicine, Inc. an Orphan Drug Designation for its EDIT-301, which is used for the treatment of sickle cell anemia.
- In October 2022, Pfizer Inc. completed the acquisition of Global Blood Therapeutics, Inc., which is involved in the development and commercialization of drugs to treat SCD.
- In February 2022, Global Blood Therapeutics Inc. received marketing approval for Oxbryta for the treatment of hemolytic anemia caused by SCD in adult and pediatric patients (12 years and above) as monotherapy or in combination with hydroxycarbamide.
Get Free Sample For